Fan, Y., Zhang, Q., Yan, M., Qu, X., Yin, Y., Sun, T., . . . Xu, B. (2025). Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy. Nature Communications, 16(1), 1. https://doi.org/10.1038/s41467-024-55090-4
Chicago-referens (17:e uppl.)Fan, Ying, et al. "Intravenous Liposomal Irinotecan in Metastatic Triple-negative Breast Cancer After ≥ 2 Prior Lines of Chemotherapy." Nature Communications 16, no. 1 (2025): 1. https://doi.org/10.1038/s41467-024-55090-4.
MLA-referens (9:e uppl.)Fan, Ying, et al. "Intravenous Liposomal Irinotecan in Metastatic Triple-negative Breast Cancer After ≥ 2 Prior Lines of Chemotherapy." Nature Communications, vol. 16, no. 1, 2025, p. 1, https://doi.org/10.1038/s41467-024-55090-4.
